Azenta, Inc.
$26.4
▲
6.85%
2026-04-21 05:32:00
www.azenta.com
NMS: AZTA
Explore Azenta, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$1.22 B
Current Price
$26.4
52W High / Low
$41.73 / $19.87
Stock P/E
—
Book Value
$37.26
Dividend Yield
—
ROCE
-1.19%
ROE
1.53%
Face Value
—
EPS
$0.58
Exp Qtr EPS
—
Sector
Healthcare
Industry
Medical Instruments & Supplies
Employees
3,000
Beta
1.47
Debt / Equity
3.18
Current Ratio
2.92
Quick Ratio
2.66
Forward P/E
20.63
Price / Sales
1.72
Enterprise Value
$667.83 M
EV / EBITDA
17.89
EV / Revenue
1.12
Rating
Buy
Target Price
$36.17
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
- Valuation is rich on a P/E basis.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Jin Medical International Ltd. | $2.08 | 13.77 | $16.4 M | — | 2.06% | 4.75% | $19.7 / $1.64 | $3.79 |
| 2. | DENTSPLY SIRONA Inc. | $12.79 | — | $2.61 B | 5.5% | 6.17% | -36.43% | $17.18 / $9.85 | $6.71 |
| 3. | ICU Medical, Inc. | $130.58 | 4,461.76 | $3.27 B | — | 3.08% | 0.04% | $160.29 / $107 | $86.03 |
| 4. | GlucoTrack, Inc. | $0.78 | — | $1.55 M | — | -524.96% | 381.2% | $15.9 / $0.62 | $3.06 |
| 5. | Microbot Medical Inc. | $2.3 | — | $154.46 M | — | -18.87% | -32.42% | $4.67 / $1.6 | $1.16 |
| 6. | ResMed Inc. | $224.49 | 22.19 | $32.69 B | 1.06% | 23.58% | 25.68% | $293.81 / $202 | $43.39 |
| 7. | Harvard Bioscience, Inc. | $6.99 | — | $30.92 M | — | 0.17% | -1.47% | $9.46 / $2.81 | $3.07 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 148.64 M | 158.95 M | 143.94 M | 143.42 M | 147.44 M | — |
| Operating Profit | -6.09 M | 1.78 M | 0.04 M | -12.57 M | -8.27 M | — |
| Net Profit | -15.43 M | 50.84 M | -52.81 M | -40.46 M | -10.99 M | — |
| EPS in Rs | -0.34 | 1.1 | -1.15 | -0.88 | -0.24 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 593.82 M | 573.45 M | 551.49 M | 555.5 M |
| Operating Profit | -21.67 M | -39.86 M | -56.67 M | -23.42 M |
| Net Profit | -55.76 M | -164.9 M | -14.64 M | 2.13 B |
| EPS in Rs | -1.21 | -3.58 | -0.32 | 46.3 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 2.06 B | 2.1 B | 2.89 B | 3.72 B |
| Total Liabilities | 332.6 M | 332.42 M | 351.22 M | 352.74 M |
| Equity | 1.73 B | 1.77 B | 2.53 B | 3.36 B |
| Current Assets | 708.34 M | 833.03 M | 1.42 B | 2.46 B |
| Current Liabilities | 237.67 M | 206.09 M | 210.93 M | 230.55 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | 72.18 M | 49.74 M | 5.83 M | -466.05 M |
| Investing CF | -90.46 M | 224.74 M | 431.38 M | 1.47 B |
| Financing CF | -9.59 M | -659.21 M | -840.46 M | -62.76 M |
| Free CF | 38.32 M | 12.35 M | -33.6 M | -543.48 M |
| Capex | -33.86 M | -37.39 M | -39.44 M | -77.44 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 3.98% | -0.72% | — | — |
| Earnings Growth % | -1026.65% | -100.69% | — | — |
| Profit Margin % | -28.76% | -2.65% | 383.95% | — |
| Operating Margin % | -6.95% | -10.28% | -4.22% | — |
| Gross Margin % | 44.4% | 43.38% | 46.01% | — |
| EBITDA Margin % | 8.87% | 5.24% | 5.45% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
| Ex Date | Dividend |
|---|---|
| 2021-12-02 | $0.1 |
| 2021-09-02 | $0.1 |
| 2021-06-03 | $0.1 |
Stock Splits
No stock split history available.